A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Incyte Corp stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 20,280 shares of INCY stock, worth $1.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,280
Previous 79,728 74.56%
Holding current value
$1.42 Million
Previous $4.83 Million 72.25%
% of portfolio
0.0%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$57.33 - $68.61 $3.41 Million - $4.08 Million
-59,448 Reduced 74.56%
20,280 $1.34 Million
Q2 2024

Jul 29, 2024

BUY
$51.18 - $63.75 $2.89 Million - $3.59 Million
56,370 Added 241.33%
79,728 $4.83 Million
Q1 2024

May 08, 2024

SELL
$56.55 - $66.59 $218,961 - $257,836
-3,872 Reduced 14.22%
23,358 $1.33 Million
Q4 2023

Feb 09, 2024

BUY
$52.16 - $64.19 $104,945 - $129,150
2,012 Added 7.98%
27,230 $1.71 Million
Q3 2023

Nov 13, 2023

BUY
$57.77 - $65.93 $290,352 - $331,364
5,026 Added 24.89%
25,218 $1.46 Million
Q2 2023

Aug 08, 2023

SELL
$60.95 - $75.51 $273,421 - $338,737
-4,486 Reduced 18.18%
20,192 $1.26 Million
Q1 2023

May 08, 2023

BUY
$70.23 - $86.01 $115,949 - $142,002
1,651 Added 7.17%
24,678 $1.78 Million
Q4 2022

Feb 09, 2023

BUY
$67.18 - $84.11 $24,655 - $30,868
367 Added 1.62%
23,027 $1.85 Million
Q3 2022

Nov 10, 2022

BUY
$66.18 - $82.86 $254,991 - $319,259
3,853 Added 20.49%
22,660 $1.51 Million
Q2 2022

Aug 04, 2022

BUY
$66.18 - $83.18 $199,665 - $250,954
3,017 Added 19.11%
18,807 $1.43 Million
Q1 2022

May 12, 2022

BUY
$66.02 - $79.71 $433,817 - $523,774
6,571 Added 71.28%
15,790 $1.25 Million
Q4 2021

Feb 09, 2022

SELL
$63.34 - $74.11 $372,249 - $435,544
-5,877 Reduced 38.93%
9,219 $677,000
Q3 2021

Nov 08, 2021

SELL
$68.67 - $84.02 $151,211 - $185,012
-2,202 Reduced 12.73%
15,096 $1.04 Million
Q2 2021

Aug 05, 2021

BUY
$79.87 - $87.53 $153,110 - $167,795
1,917 Added 12.46%
17,298 $1.46 Million
Q1 2021

May 05, 2021

SELL
$76.02 - $100.5 $1,368 - $1,809
-18 Reduced 0.12%
15,381 $1.25 Million
Q4 2020

Feb 12, 2021

BUY
$80.74 - $97.7 $135,481 - $163,940
1,678 Added 12.23%
15,399 $1.34 Million
Q3 2020

Nov 09, 2020

SELL
$85.07 - $109.69 $1.72 Million - $2.22 Million
-20,229 Reduced 59.58%
13,721 $1.23 Million
Q2 2020

Aug 04, 2020

SELL
$74.18 - $108.93 $5.77 Million - $8.47 Million
-77,769 Reduced 69.61%
33,950 $3.53 Million
Q1 2020

May 12, 2020

BUY
$63.18 - $85.97 $3.14 Million - $4.27 Million
49,629 Added 79.93%
111,719 $8.18 Million
Q4 2019

Feb 11, 2020

SELL
$73.04 - $95.72 $1.4 Million - $1.83 Million
-19,104 Reduced 23.53%
62,090 $5.42 Million
Q3 2019

Nov 12, 2019

SELL
$72.82 - $86.52 $3.21 Million - $3.81 Million
-44,078 Reduced 35.19%
81,194 $6.03 Million
Q2 2019

Aug 02, 2019

BUY
$73.52 - $88.7 $126,380 - $152,475
1,719 Added 1.39%
125,272 $10.6 Million
Q1 2019

Apr 26, 2019

BUY
$63.56 - $88.17 $7.54 Million - $10.5 Million
118,574 Added 2381.48%
123,553 $10.6 Million
Q4 2018

Feb 13, 2019

BUY
$58.5 - $69.94 $16,146 - $19,303
276 Added 5.87%
4,979 $310,000
Q3 2018

Nov 13, 2018

SELL
$61.75 - $74.23 $6,113 - $7,348
-99 Reduced 2.06%
4,703 $325,000
Q2 2018

Aug 01, 2018

BUY
$60.85 - $83.98 $72,837 - $100,524
1,197 Added 33.2%
4,802 $322,000
Q1 2018

May 07, 2018

SELL
$83.06 - $100.98 $2.46 Million - $2.99 Million
-29,644 Reduced 89.16%
3,605 $300,000
Q4 2017

Feb 01, 2018

SELL
$93.56 - $116.6 $1.5 Million - $1.87 Million
-16,042 Reduced 32.55%
33,249 $3.15 Million
Q3 2017

Nov 02, 2017

BUY
$109.15 - $138.27 $5.38 Million - $6.82 Million
49,291
49,291 $5.75 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.6B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Bnp Paribas Asset Management Holding S.A. Portfolio

Follow Bnp Paribas Asset Management Holding S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bnp Paribas Asset Management Holding S.A., based on Form 13F filings with the SEC.

News

Stay updated on Bnp Paribas Asset Management Holding S.A. with notifications on news.